Bellevue Life Sciences Acquisition CORP

OSR Health announces Nasdaq communication confirming its Shareholder Loyalty CVR program will not trigger mechanical price adjustments for common stock.

OSR Health, Inc. (formerly OSR Holdings, Inc.) has officially changed its corporate name and revived its Delaware charter, effective June 11, 2026.

OSR Holdings, Inc. has postponed its 2026 Annual Meeting of Stockholders, originally scheduled for June 18, 2026, to allow for further evaluation of matters related to the meeting.

OSR Holdings, Inc. has entered into an Asset Purchase Agreement to acquire the VXM01 intellectual property family from its indirect subsidiary, Vaximm AG, for $30 million.

OSR Holdings, Inc. has filed an independent fairness opinion from Avance Life Sciences AG regarding its $815 million global license agreement for the VXM01 asset with BCM Europe AG.

OSR Holdings, Inc. has entered into a global exclusive license agreement with its largest shareholder, BCM Europe AG, for its VXM01 cancer immunotherapy platform, potentially worth up to $815 million in milestone payments.

OSR Holdings reported a 36% decrease in net sales for Q1 2026, but saw gross profit margins improve to 33% due to a shift to a consignment model.

OSR Holdings, Inc. reported increased operating and net losses for the nine months ended September 30, 2025, driven by public company costs and merger expenses, while announcing a strategic acquisition and ongoing capital raises.

OSR Holdings, Inc. reported increased losses for the first half of 2025 due to merger-related expenses, while advancing strategic initiatives including a new acquisition and equity tokenization plans.

OSR Holdings' Q1 2025 net sales decreased by 16% compared to Q1 2024, primarily due to the termination of a key customer relationship.

Bellevue Life Sciences Acquisition Corp. reported a net loss for the third quarter of 2024 and is navigating ongoing challenges with Nasdaq listing requirements while pursuing a business combination.

Bellevue Life Sciences Acquisition Corp. reported a net loss for the second quarter of 2024 and is facing substantial doubt about its ability to continue as a going concern due to liquidity issues.

OSR Holdings, Inc. reported a significant increase in net loss for fiscal year 2025, driven by higher operating expenses and one-time merger-related costs, while advancing its biotech pipeline and expanding its medical device distribution business.

OSR Holdings, a global healthcare company, finalized its merger with Bellevue Life Sciences Acquisition Corp., but faces immediate financial challenges due to a canceled PIPE investment and existing debt.

Bellevue Life Sciences Acquisition Corp.'s 10-K filing details its financial status, ongoing efforts to secure a business combination, and strategic focus on the healthcare sector.

Bellevue Global Life Science Investors LLC reports acquiring 43,000 shares of OSR Holdings, Inc. common stock following the conversion of private placement rights related to a business combination.

Kuk Hyoun Hwang, President and CEO of OSR Holdings, reports the acquisition of shares through conversions and a business combination, significantly increasing his indirect beneficial ownership.

Bellevue Life Sciences Acquisition Corp. (BLAC) finalizes its business combination with OSR Holdings Co., Ltd., changing its name to OSR Holdings, Inc. and preparing to trade on the Nasdaq.

Bellevue Life Sciences Acquisition Corp. has amended its business combination agreement with OSR Holdings and its PIPE subscription agreement with Toonon Partners, modifying redemption features and put/call rights.

Bellevue Life Sciences Acquisition Corp. has extended a $300,000 loan to OSR Holdings Co., Ltd. to support working capital and other expenses.

Bellevue Life Sciences Acquisition Corp. has entered into a subscription agreement with Toonon Partners Co., Ltd. for a $20 million PIPE investment to support its business combination with OSR Holdings Co., Ltd.

OSR Health, Inc. has announced its 2026 Annual Meeting of Stockholders to be held virtually on August 7, 2026, proposing the re-election of directors, ratification of auditors, an advisory vote on executive compensation, and a significant increase in authorized shares.

OSR Holdings, Inc. is holding its annual meeting on June 18, 2026, to elect directors, ratify auditors, approve executive compensation, amend its omnibus incentive plan, and change its corporate name to OSR Health, Inc.

OSR Holdings, Inc. is seeking shareholder approval for the election of seven directors, an advisory vote on executive compensation, the adoption of new equity incentive plans, and a significant common share issuance that could exceed 20% of outstanding stock, potentially leading to dilution.

Bellevue Life Sciences Acquisition Corp. is seeking stockholder approval to extend the deadline for completing a business combination and to remove a net tangible asset requirement from its charter.

Bellevue Life Sciences Acquisition Corp. is seeking stockholder approval to extend the deadline for completing a business combination from May 14, 2024, to November 14, 2024.

OSR Holdings, a global healthcare holding company, has filed an amended registration statement to allow for the resale of up to 15.41 million shares by White Lion Capital, potentially securing up to $83.9 million in new capital through equity line, warrant, and convertible note agreements, while reporting a significant net loss for Q1 2025.

OSR Holdings, a global healthcare holding company, reported a significant increase in net loss and a decrease in net sales for Q1 2025, while securing new dilutive financing agreements to address liquidity challenges following a cancelled $20 million PIPE transaction.

Joint Protein Central Inc. has filed a Schedule 13G reporting a 7.9% beneficial ownership stake in OSR Holdings, Inc.

An amended Schedule 13G filing confirms that Bellevue Global Life Science Investors, LLC, BCM Europe AG, Bellevue Capital Management LLC, and Kuk Hyoun Hwang collectively maintain significant beneficial ownership in Bellevue Life Sciences Acquisition Corp.

RiverNorth Capital Management, LLC has reported that it no longer holds a beneficial ownership stake in Bellevue Life Sciences Acquisition Corp., with its ownership falling to 0% as of December 31, 2024.